Supplementary Methods

Study Populations
Costa Rica: The primary study population consisted of 58 subjects with (cases) and 57 subjects without (controls) COPD in the Genetic Epidemiology of COPD in Costa Rica (GECCOR) study. Cases were recruited from patients attending four adult hospitals in San José (Costa Rica) and their affiliated clinics, and through newspaper ads. Control subjects were recruited from individuals attending a smoking-cessation clinic at the Institute for Pharmaco-dependency in San José, and through newspaper ads. All of these control subjects had no addictions other than to nicotine as determined by phone questionnaire. To ensure their descent from the founder population of the Central Valley of Costa Rica (which is predominantly of Spanish and Native American ancestry), all participants were required to have at least six great-grandparents born in the Central Valley of Costa Rica. Additional inclusion criteria for cases were age 21 to 71 years, physician-diagnosed COPD, ≥ 10 pack-years of cigarette smoking, and an FEV1 ≤ 65% predicted and an FEV1/FVC ratio of ≤ 70% after bronchodilator administration. Controls were recruited on the basis of the same criteria for age and smoking history, but they had to have no physician-diagnosed COPD and normal spirometry. Exclusion criteria for cases and controls included history of chronic pre-existing chronic lung disease (e.g., bronchiectasis). Preexisting lung disease was determined by physician diagnosis, CT scans (41/58 cases), and subject questionnaire. Controls who had significant dyspnea, cough, or wheezing without a formal pulmonary diagnosis were also excluded. ) and emphysema on computed tomographic (CT) imaging of the chest. The NETT Genetics Ancillary Study contains a subset of the original cohort with blood available for genotyping.
After providing written informed consent, NETT participants provided a blood sample for DNA extraction for genetic studies of COPD. The study was approved by the institutional review boards at participating NETT centers. A total of 382 self-reported white subjects without severe alpha-1 antitrypsin deficiency were included in this study.
Normative Aging Study (NAS): The Normative Aging Study is an ongoing longitudinal study of healthy men established in 1963 and conducted by the Veterans Administration (VA) 5 . Briefly, men from the greater Boston area, ages 21 to 80 years, enrolled in the study after an initial health screening determined that they were free of known chronic medical conditions. Since enrollment, the participants have undergone comprehensive clinical examinations at 5-year intervals for those < 52 years old and at 3-year intervals for those > 52 years old. Selection of controls for COPD genetic studies from this population has been described previously 6 ; self-reported white control subjects had DNA available for genotyping, a history of at least 10 pack-years of cigarette smoking and no evidence for airflow obstruction by spirometry 2 at their most recent visit (FEV1 > 80% predicted 7 and FEV1/FVC > 90% predicted 4 . Anonymized data were used, as approved by the institutional review boards of Partners Healthcare System and the Boston VA. A total of 453 subjects meeting enrollment criteria were included in this study.
Norway: Details on the Bergen, Norway case-control study have been described previously 8 . Subjects
were recruited from Bergen, Norway, and in contrast to the NAS and ECLIPSE studies, were required to have > 2.5 pack years of smoking history. GOLD Stage II or greater COPD cases were diagnosed by post-bronchodilator spirometry2 (FEV1 < 80% predicted and FEV1/FVC < 0.7), while controls had normal spirometry (FEV1 > 80% predicted and FEV1/FVC > 0.7). Subjects with alpha-1 antitrypsin genotypes PI ZZ, ZNull, Null-Null or SZ were excluded. All subjects gave informed consent, and the appropriate institutional review boards approved the study. A total of 933 cases and 919 controls of self-identified white ethnicity were included in this study.
Lovelace Smokers Cohort: Details on the Lovelace Smokers Cohort have been published previously. 9 Our top two SNPs in FGF7 were replicated using a Taqman assay (Applied Biosystems, Foster City, CA). All subjects gave informed consent, and the institutional review board of the Lovelace Respiratory
Institute approved the study. COPD was classified based on an FEV1/FVC ratio below the 5 th percentile of the predicted value, also referred to as the lower limit of normal (LLN).
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Genotyping and Quality Control
Genotyping of NETT,NAS,Norway, and ECLIPSE has been described in detail previously 11 .
For the Costa Rica cohort, genotyping was performed on the Illumina Quad 610 platform (Illumina, Inc;
San Diego,CA) at the Channing Laboratory, Brigham and Women's Hospital. Cases and controls were randomly allocated in batches, which included at least one replicate sample. First pass cleaning using two-channel intensity was performed using Beadstudio. Although subjects with <95% of markers genotyped, and SNPs with a call frequency < 95% were to be removed a priori, all genotyped subjects passed with an average call rate of 99.87%. The remaining markers were cleaned following Illumina guidelines.
(http://www.illumina.com/documents/products/technotes/technote_infinium_genotyping_data_analysis.
pdf)
SNPs with a call frequency between 0.9 and 0.99 and a cluster separation below 0.3 were manually inspected, with a threshold set for each workspace below which no SNPs were deemed unambiguous.
We additionally examined SNPs with a low ABR mean, ABT mean, and heterozygote excess. X, Y, and mitochondrial SNPs were excluded from analysis.
Subject and Marker Cleaning
For the Costa Rica cohort, BeadStudio workspaces were exported to ped file format and further quality control assessment was performed using Python (www.python.org) and R (www.r-project.org) scripts in conjunction with PLINK (1.05) 12 . Quality control of genotyping data was assessed by subject and by marker. Subject data were excluded after examining missingness, reproducibility and discordances, relatedness, sex, and inbreeding. Subjects with discordance > 1% in replicate genotyping were discarded. Relatedness was examined using rgGrr 13 and estimated IBD in PLINK, using a cutoff of 0.12513. Within each set of related subjects, unrelated individual(s) were chosen based on phenotypic criteria. In addition to testing for relatedness within each cohort, a test for relatedness between cohorts was performed prior to construction of the primary (merged) dataset. Sex assignment was based on X homozygosity estimates, with those > 0.8 as male, and < 0.2 as female. Discordant samples were removed. Inbreeding coefficients > |0.2| were removed. Finally, among samples run in replicate, the sample with the higher passing genotype rate was chosen.
Markers were excluded based on missingness, minor allele frequency, reproducibility, and HardyWeinberg equilibrium. Markers with missingness > 5% were excluded. A strict minor allele frequency cutoff was not specified; instead, markers that were monoallelic or singleton in each dataset were excluded. Within replicates, SNPs showing significant discordance (examining the distribution of discordances) were excluded. Markers with Hardy-Weinberg deviation -P value less than .01 -were also excluded. Differential missingness between cases and controls was assessed, but not used to exclude markers at this stage. A summary of the quality control measures is shown in Supplementary   Table 1 .
Construction of RCHH
Regions of conserved homozygosity haplotype (RCHHs) were identified using the method described by Miyazawa et. al. 14 . In brief, for any given individual all heterozygous SNPs were ignored and the SNP location was scored with the value of the allele for that subject. Subjects are compared only across SNPs that are scored. RCHH are defined by runs of SNPs that share the same allele at the homozygous locations across multiple subjects, ignoring heterozygous SNPs. The size of the shared segments between any two individuals was set at 3.0 cM, which is a size designed to reduce the false positive and false negative rates of discovery. A theoretical ancestral segment is then constructed from the largest subgroup of subjects sharing a particular RCHH (see Supplementary Figure 1 ). While any two subjects much have at least 3.0 cM of sharing, the size may be much smaller when comparing across multiple subjects (Supplementary figure 2) . The total number of cases and controls sharing this ancestral allele is used to calculate a P value based on a standard normal distribution.
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